Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the α5β1 integrin

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer

(2016) M. Hussain et al.   CLINICAL CANCER RESEARCH

Tissue engineering a surrogate niche for metastatic cancer cells

(2015) F. Philipp Seib et al.   BIOMATERIALS

Making sense of hematopoietic stem cell niches

(2015) P. E. Boulais et al.   BLOOD

Humanized mice models for primary bone tumor and bone metastasis research

(2015) Laure Thibaudeau et al.   CELL CYCLE

A d-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization

(2014) Donna M. Veine et al.   CLINICAL & EXPERIMENTAL METASTASIS

Matricryptins and matrikines: biologically active fragments of the extracellular matrix

(2014) Sylvie Ricard-Blum et al.   EXPERIMENTAL DERMATOLOGY

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

(2014) Oliver Sartor et al.   LANCET ONCOLOGY

Current understanding of the thrombospondin-1 interactome

(2014) Andrea Resovi et al.   MATRIX BIOLOGY

Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor

(2013) Aaron Rosenberg et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

(2013) C. Parker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors

(2013) Florence Schaffner et al.   Cancers

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

(2012) B. Besse et al.   ANNALS OF ONCOLOGY

Volociximab in cancer

(2011) Salah Almokadem et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

(2011) Katherine M. Bell-McGuinn et al.   GYNECOLOGIC ONCOLOGY

Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow

(2011) Yusuke Shiozawa et al.   JOURNAL OF CLINICAL INVESTIGATION

Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4

(2011) M P Rettig et al.   LEUKEMIA

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

(2010) Deborah A. Bradley et al.   INVESTIGATIONAL NEW DRUGS

Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

(2010) Simón Méndez-Ferrer et al.   NATURE

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds  5 1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

(2008) A. D. Ricart et al.   CLINICAL CANCER RESEARCH